GlobeNewswire: Industry News on Medical Equipment Contains the last 10 of 28750 releaseshttp://www.globenewswire.com/External?Length=42024-03-28T20:49:47ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2024/03/28/2854473/0/en/Femasys-Announces-Financial-Results-for-Year-Ended-December-31-2023-and-Provides-Corporate-Update.html?f=22&fvtc=3&fvtv=4535Femasys Announces Financial Results for Year Ended December 31, 2023 and Provides Corporate Update2024-03-28T20:05:00Z<![CDATA[Following FDA Clearance of FemaSeed®, Company Secures Capital to Support Commercial Initiatives; Cash Expected to Fund Operations Into 2H 2025 Following FDA Clearance of FemaSeed®, Company Secures Capital to Support Commercial Initiatives; Cash Expected to Fund Operations Into 2H 2025]]>https://www.globenewswire.com/news-release/2024/03/28/2854245/0/en/Milestone-Scientific-Schedules-2023-Year-End-Financial-Results-and-Business-Update-Conference-Call.html?f=22&fvtc=3&fvtv=4535Milestone Scientific Schedules 2023 Year-End Financial Results and Business Update Conference Call2024-03-28T15:45:00Z<![CDATA[ROSELAND, N.J., March 28, 2024 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments, that provide painless and precise injections, today announced that it will host a conference call at 8:30 AM Eastern Time on Monday, April 1, 2024, to discuss the company’s financial results for 2023, as well as the company’s corporate progress and other developments]]>https://www.globenewswire.com/news-release/2024/03/28/2854056/0/en/JenaValve-Announces-Publication-of-ALIGN-AR-Pivotal-Trial-Results-in-The-Lancet.html?f=22&fvtc=3&fvtv=4535JenaValve Announces Publication of ALIGN-AR Pivotal Trial Results in The Lancet2024-03-28T13:00:00Z<![CDATA[IRVINE, Calif., March 28, 2024 (GLOBE NEWSWIRE) -- JenaValve Technology, Inc., developer and manufacturer of the Trilogy™ Transcatheter Heart Valve (THV) System, today announced the publication of results from the ALIGN-AR Pivotal Trial in The Lancet. The ALIGN-AR trial is a prospective, multicenter study evaluating the use of JenaValve’s Trilogy transcatheter heart valve in high-risk patients with symptomatic moderate-to-severe or severe aortic regurgitation.]]>https://www.globenewswire.com/news-release/2024/03/28/2854002/0/en/Assure-Holdings-Closes-Sale-of-Certain-Assets-to-MPOWERHealth.html?f=22&fvtc=3&fvtv=4535Assure Holdings Closes Sale of Certain Assets to MPOWERHealth2024-03-28T12:30:00Z<![CDATA[DENVER, March 28, 2024 (GLOBE NEWSWIRE) -- Assure Holdings Corp. (the “Company” or “Assure”) (NASDAQ: IONM), a provider of intraoperative neuromonitoring (“IONM”) and remote neurology services, today announced that it closed the sale of certain assets of its IONM business to MPOWERHealth on March 26, 2024. The sale includes proceeds of up to $4.5 million, of which $2.32 million was paid in cash at the initial closing and up to an additional $2.18 million to be paid in relation to a potential earnout payment tied to case volume from the acquired assets during the 12-month period following the initial closing. The asset sale includes most of the Company’s healthcare facility contracts and clinical equipment, and a majority of the Company’s employees. The Company retains certain of its assets, including but not limited to, its accounts receivable and its employees in the revenue cycle management team.]]>https://www.globenewswire.com/news-release/2024/03/28/2854008/0/en/Nexalin-Technology-Announces-Positive-Results-of-Clinical-Study-Validating-its-Gen-2-tACS-Device-for-Reducing-Pain-Among-Veterans-with-Mild-Traumatic-Brain-Injury-at-University-of-.html?f=22&fvtc=3&fvtv=4535Nexalin Technology Announces Positive Results of Clinical Study Validating its Gen-2 tACS Device for Reducing Pain Among Veterans with Mild Traumatic Brain Injury at University of California, San Diego2024-03-28T12:30:00Z<![CDATA[Collaborative Study involving the VA and UCSD achieved statistically significant decrease in PCS and PTSD symptoms versus control group]]>https://www.globenewswire.com/news-release/2024/03/28/2853874/0/en/Quipt-Home-Medical-Announces-Voting-Results-from-Its-Annual-General-and-Special-Meeting-of-Shareholders.html?f=22&fvtc=3&fvtv=4535Quipt Home Medical Announces Voting Results from Its Annual General and Special Meeting of Shareholders2024-03-28T11:30:00Z<![CDATA[CINCINNATI, March 28, 2024 (GLOBE NEWSWIRE) -- Quipt Home Medical Corp. (the “Company”) (NASDAQ: QIPT) (TSX: QIPT), a U.S. based home medical equipment provider, focused on end-to-end respiratory care, today announced the voting results from its annual general and special meeting of shareholders held on March 27, 2024 (the “Meeting”) in Wilder, Kentucky. The total number of shares represented in person or by proxy at the Meeting was 25,432,699, representing 60.4% of the total issued and outstanding shares in the capital of the Company.]]>https://www.globenewswire.com/news-release/2024/03/28/2853736/0/en/Sequana-Medical-announces-2023-Full-Year-Results-and-2024-Outlook.html?f=22&fvtc=3&fvtv=4535Sequana Medical announces 2023 Full Year Results and 2024 Outlook2024-03-28T07:00:00Z<![CDATA[PRESS RELEASEREGULATED INFORMATION – INSIDE INFORMATION28 March 2024, 08:00 a.m. CET]]>https://www.globenewswire.com/news-release/2024/03/28/2853689/0/en/Cannabix-Technologies-Announces-Resignation-of-Kulwant-Malhi.html?f=22&fvtc=3&fvtv=4535Cannabix Technologies Announces Resignation of Kulwant Malhi2024-03-28T02:00:00Z<![CDATA[VANCOUVER, British Columbia, March 27, 2024 (GLOBE NEWSWIRE) -- Cannabix Technologies Inc. (CSE: BLO) (OTC PINK: BLOZF) (the “Company or Cannabix”) reports that Kulwant Malhi has resigned as President and Director of the Company.]]>https://www.globenewswire.com/news-release/2024/03/27/2853535/0/en/Applied-UV-Inc-Announces-Pricing-of-2-76-Million-Registered-Direct-and-Private-Placement-Priced-at-the-Market-Under-Nasdaq-Rules.html?f=22&fvtc=3&fvtv=4535Applied UV, Inc. Announces Pricing of $2.76 Million Registered Direct and Private Placement Priced at the Market Under Nasdaq Rules2024-03-27T18:35:40Z<![CDATA[NEW YORK, NY, March 27, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- Applied UV, Inc. (NASDAQ: AUVI; AUVIP) (“Applied UV” or the “Company”), a leader in smart building technology solutions, today announced that it has entered into definitive agreements with institutional investors for the purchase and sale of common stock of the Company (“Common Stock”) and pre-funded warrants (“Pre-Funded Warrants”) in a registered direct offering. In a concurrent private placement, the Company also agreed to sell to the same investors, common warrants (“Common Warrants”). Aggregate gross proceeds to the Company from both transactions are expected to be approximately $2.76 million, the maximum availability under the effective shelf registration statement.]]>https://www.globenewswire.com/news-release/2024/03/27/2853305/0/en/Synaptive-Medical-Receives-FDA-510-k-Clearance-for-Near-Infrared-Fluorescence-Visualization-Expanding-Application-of-Existing-Robotic-Exoscope.html?f=22&fvtc=3&fvtv=4535Synaptive Medical Receives FDA 510(k) Clearance for Near-Infrared Fluorescence Visualization, Expanding Application of Existing Robotic Exoscope2024-03-27T14:00:00Z<![CDATA[TORONTO, March 27, 2024 (GLOBE NEWSWIRE) -- Synaptive Medical Inc., a global med tech and technology company solving surgical, imaging and data challenges, has received 510(k) clearance from the Food and Drug Administration (FDA) for its Near-Infrared fluorescence visualization module, Modus IR, adding to the existing fluorescence offering on its 4K 3D robotic exoscope, Modus X.]]>Modus X robotic exoscope from Synaptive MedicalFigure 1